• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Why the AnteoTech Share Price Fell 7% Today (ASX:ADO)

Like 0

By Lachlann Tierney, Monday, 03 May 2021

The AnteoTech Ltd [ASX:ADO] share price is down 7% today. Can ADO’s recent cash flow report explain the fall? ADO shares fell as much as 9.2% in early trade...

The AnteoTech Ltd [ASX:ADO] share price is down 7% today. Can ADO’s recent cash flow report explain the fall?

ADO shares fell as much as 9.2% in early trade and currently exchange hands for 40.5 cents a share.

While down today, the ADO share price is still up 285% year-to-date and up 1,740% over the last 12 months.

ASX ADO - AnteoTech Share Price ChartSource: Tradingview.com

ADO’s cash flow status

ADO released its quarterly cash flow and activities reports last Friday.

Could its share price slump reflect the market’s delayed reaction to the reports as it mulled over the numbers over the weekend?

Let’s look at AnteoTech’s cash flow position for the quarter ended 31 March 2021.

ADO recorded $112,000 from customer receipts for the March quarter and $675,000 year-to-date (nine months).

These inflows were offset by operating expenses including $728,000 spent on research and development, and $668,000 on staff costs.

In total, AnteoTech recorded a net loss from operating activities of $1.37 million.

Having started the quarter with $6.43 million in cash, ADO ended the March quarter with $5.13 million.

With this cash balance and cash outgoings of $1.37 million, AnteoTech only had 3.7 estimated quarters of funding available at quarter’s end.

Some investors may have been unimpressed with this quarterly cash flow report and decided to exit their positions.

However, investors would have been aware that AnteoTech’s cash burn prompted the company to secure fresh funding last week.

AnteoTech secures $12 million

As we’ve covered here, last week ADO received firm commitments to raise $12 million before costs by issuing more than 46 million new fully paid ordinary shares at 26 cents per share.

The company plans to launch a share purchase plan to raise a further $4 million from ‘eligible, existing shareholders’ at 26 cents per share.

The offer price represents a 20.3% discount to ADO’s 10-day volume-weighted average price.

Importantly, the funds will be used to scale up the rollout of AnteoTech’s EuGeni reader and in vitro rapid diagnostic test for the detection of SARS-CoV-2 nucleocapsid antigen.

It looks like ADO’s immediate focus is on its COVID-19 testing products.

And this could potentially offer another reason for today’s share price slump.

Investors who purchased ADO stock for its ongoing research into improving the energy storage capacity of lithium ion battery anodes may have been disappointed by ADO’s focus on its life science products.

Especially when the lithium sector is heating up.

Given ADO’s March quarter cash position, the $12 million capital raise was needed.

But some investors may think that earmarking the funds primarily for its life science products will sideline ADO’s lithium-ion battery segment.

That said, AnteoTech might think prioritising its COVID testing products is the best direction for the medium-term.

For instance, the March quarter saw ADO pocket a $1.4 million Queensland government grant to develop and commercialise its COVID-19 ART.

Maybe the company sees its life science segment as the segment with the quickest path to commercialisation.

If smaller-cap stocks like AnteoTech interest you but you’re unsure how to find ones with great potential, then I think you will enjoy reading this free report on four high-value small-caps.

Small-cap investment is all about information advantage, so I highly recommend reading through the report.

Regards,

Lachlann Tierney

For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • As Political Dumb-Wits Beat the Drums of War: Keep Commodities Front and Centre
    By James Cooper

    In today’s edition, James Cooper looks at the growing hostilities between Pakistan and India through the lens of the commodity cycle. And why it could matter more than most think.

  • The share market bears have no answer to this…
    By Callum Newman

    I came across a handy bit of info from Wilson Asset Management yesterday. Wilson says that there’s strong demand for Chinese assets despite the recent volatility and trade tensions. Why do we care? There could be profit in this.

  • The method in Trump’s tariff madness
    By Jim Rickards

    Trump is pursuing a twenty-first-century version of what was originally known as the American System. A system that made America great in the first place.

Primary Sidebar

Latest Articles

  • As Political Dumb-Wits Beat the Drums of War: Keep Commodities Front and Centre
  • The share market bears have no answer to this…
  • The method in Trump’s tariff madness
  • The first place to look thanks to the US/China truce
  • The trade war is over. Tax cut chaos is next.

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988